Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15085010 | 0.90 | KCNE1 (0.42) | KCNE1CCR1KCNQ1RNASEH1 | |
| SCHEMBL22400287 | 0.90 | KCNE1 (0.42) | KCNE1CCR1KCNQ1RNASEH1ERCC1 | |
| SCHEMBL16445001 | 0.89 | RNASEH1 (0.38) | KCNE1CCR1KCNQ1RNASEH1ERCC1 | |
| SCHEMBL17749053 | 0.80 | ERCC1 (0.48) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL15085016 | 0.79 | KCNE1 (0.69) | KCNE1CCR1KCNQ1ERCC1FEN1 | |
| SCHEMBL9979025 | 0.77 | KCNE1 (0.51) | KCNE1CCR1KCNQ1ERCC1FEN1 | |
| SCHEMBL16453964 | 0.77 | KCNE1 (0.65) | KCNE1CCR1KCNQ1 | |
| SCHEMBL13041232 | 0.77 | ERCC1 (0.50) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL12432516 | 0.76 | ERCC1 (0.49) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL15728533 | 0.70 | KCNE1 (0.40) | KCNE1CCR1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804607-B1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2020-09-16 | — | — | EP | claimed |
| US-9403809-B2 | Synthesis of raltegravir | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-08-02 | — | — | US | claimed |
| US-20150045554-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-02-12 | — | — | US | claimed |
| EP-2804607-B1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2020-09-16 | — | — | EP | disclosed |
| EP-2804607-B1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2020-09-16 | — | — | EP | disclosed |
| US-20160311810-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311810-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LTD (IN) | 2016-10-27 | — | — | US | disclosed |
| US-9475799-B1 | Synthesis of Raltegravir | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9475799-B1 | Synthesis of Raltegravir | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-10-25 | — | — | US | disclosed |
| US-9403809-B2 | Synthesis of raltegravir | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-9403809-B2 | Synthesis of raltegravir | EMCURE PHARMACEUTICALS LIMITED (IN) | 2016-08-02 | — | — | US | disclosed |
| US-20150045554-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-02-12 | — | — | US | disclosed |
| US-20150045554-A1 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2015-02-12 | — | — | US | disclosed |
| EP-2804607-A2 | SYNTHESIS OF RALTEGRAVIR | Emcure Pharmaceuticals Limited (IN) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013098854-A2 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013098854-A2 | SYNTHESIS OF RALTEGRAVIR | EMCURE PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311810-A1 | SYNTHESIS OF RALTEGRAVIR | CYP3A4, CYP3A5, IMPDH1 | KCNE1 3488/4885CCR1 2197/4885KCNQ1 3105/4885 |
| US-20150045554-A1 | SYNTHESIS OF RALTEGRAVIR | CYP3A4, CYP3A5, IMPDH1 | KCNE1 3488/4885CCR1 2197/4885KCNQ1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.